Commerzbank Aktiengesellschaft FI Makes New Investment in Humana Inc. $HUM

Commerzbank Aktiengesellschaft FI bought a new stake in shares of Humana Inc. (NYSE:HUM) in the first quarter, HoldingsChannel reports. The institutional investor bought 2,625 shares of the insurance provider’s stock, valued at approximately $455,000.

Several other hedge funds have also made changes to their positions in HUM. Aberdeen Group plc raised its holdings in shares of Humana by 18.1% in the 4th quarter. Aberdeen Group plc now owns 283,778 shares of the insurance provider’s stock valued at $72,684,000 after purchasing an additional 43,442 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Humana by 4.1% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 250,330 shares of the insurance provider’s stock worth $66,207,000 after purchasing an additional 9,960 shares during the period. Ninety One UK Ltd boosted its stake in shares of Humana by 57.2% during the fourth quarter. Ninety One UK Ltd now owns 112,501 shares of the insurance provider’s stock valued at $28,815,000 after purchasing an additional 40,958 shares in the last quarter. Sustainable Insight Capital Management LLC increased its holdings in Humana by 23.7% during the fourth quarter. Sustainable Insight Capital Management LLC now owns 24,757 shares of the insurance provider’s stock valued at $6,341,000 after buying an additional 4,740 shares during the period. Finally, Swedbank AB increased its holdings in Humana by 6.2% during the fourth quarter. Swedbank AB now owns 111,803 shares of the insurance provider’s stock valued at $28,636,000 after buying an additional 6,534 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of HUM opened at $397.93 on Thursday. The company has a market cap of $47.78 billion, a price-to-earnings ratio of 42.56, a price-to-earnings-growth ratio of 2.20 and a beta of 0.71. Humana Inc. has a twelve month low of $163.11 and a twelve month high of $428.88. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.66. The company has a 50 day moving average of $360.55 and a two-hundred day moving average of $263.22.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.97 by $0.34. The business had revenue of $39.65 billion for the quarter, compared to the consensus estimate of $39.37 billion. Humana had a return on equity of 10.45% and a net margin of 0.82%.The business’s quarterly revenue was up 23.5% on a year-over-year basis. During the same period in the prior year, the firm posted $11.58 earnings per share. Humana has set its FY 2026 guidance at 9.000- EPS. As a group, analysts predict that Humana Inc. will post 9.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HUM has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft downgraded shares of Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, May 20th. Robert W. Baird cut their price target on Humana from $264.00 to $205.00 and set a “neutral” rating on the stock in a report on Wednesday, April 15th. Barclays boosted their price target on Humana from $180.00 to $344.00 and gave the stock an “equal weight” rating in a research report on Tuesday, May 26th. Guggenheim raised their price objective on Humana from $252.00 to $269.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Finally, Leerink Partners lifted their target price on Humana from $185.00 to $255.00 and gave the company a “market perform” rating in a research note on Thursday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $327.17.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.